



## **IBCN Update Series**

**Sept 25<sup>th</sup>, 2021**

**Oct 30<sup>th</sup>, 2021**

**Dec 4<sup>th</sup>, 2021**

**Virtual Meeting**

## Platinum Sponsors



## Gold Sponsors



## Silver Sponsors





**Please tweet about IBCN 2021!**

**#IBC2021**

**@IBC1997**

**IBCN Update on ctDNA**  
**September 25th, 2021**  
**1600-1730 CET**

Moderator: Tilman Todenhöfer

1600 ctDNA: Molecular residual disease and treatment response measurements

- Lars Dyrskjøt

1615 ctDNA: Insights into biology of urothelial carcinoma

- Alex Wyatt

1630 ctDNA in the clinic and clinical trials

- Matt Galsky

1645 Panel discussion with Q&A

**IBCN Update on Bladder Preservation after Neoadjuvant Therapy**  
**October 30th, 2021**  
**1600-1730 CET**

Moderator: Ashish Kamat & Stephen Williams

1600 Clinical staging after NAC

- Roland Seiler

1610 Experience with bladder sparing after clinical complete response to neoadjuvant chemotherapy

- Harry Herr

1615 Biology of DNA Damage Repair Gene Alterations

- Kent Mouw

1630 Marker driven bladder preservation - clinical trial update

- Gopa Iyer

1645 Panel discussion with Q&A

## **IBCN Update on Biology of BCG Response**

**December 4th, 2021**

**1600-1730 CET**

Moderators: Lars Dyrskjøt & Roman Nawroth

1600 BCG immunology and sexual dimorphism in bladder immunity

- Molly Ingersoll

1615 Somatic features of response to BCG

- David Müller

1625 Transcriptomic correlates to BCG response

- TCM Zuiverloon

1635 Multi-omics correlates to BCG response

- Trine Strandgaard

1645 Immunophenotyping of BCG response and resistance

- Amir Horowitz

1700 Clinical trial update

- Josh Meeks

1707 Clinical trial concept

- John Sfakianos

1710 Panel discussion with Q&A